Understanding the evolving safety landscape in autologous and allogeneic CAR-T therapy

Immuno-Oncology Insights 2022; 3(6), 339–343

DOI: 10.18609/ioi.2021.034

Published: 7 June 2022
Viewpoint
Elaine Murray McCracken

“ There is a huge – and understandable – focus on efficacy, but we must also keep our eyes on safety.”